Following the discovery by Johnson, Anker, and Meleney of the polypeptide antibiotic substance, bacitracin, in culture filtrates of a strain of B. subtilis (1) , this drug has been administered to a large number of patients with a variety of bacterial infections (2) (3) (4) (5) .
In early clinical studies, recognition of the toxic manifestations of bacitracin lagged behind observations on the therapeutic efficacy of this antibiotic. Recent reports, however, have indicated an increasing awareness of the nephrotoxic properties of commercial preparations of bacitracin administered parenterally to the human (2, 5) .
Animal studies have demonstrated that bacitracin is nephrotoxic for the mouse, rat, and monkey. Following parenteral administration of bacitracin in the mouse, tubular degeneration and necrosis occurred. Although the glomerular tuft appeared normal, Bowman's space was distended with coagulum (6) . Similar findings of tubular injury have been reported in the rat (7) . Following the administration of bacitracin in the monkey, proteinuria and glycosuria occurred. Again the histologic findings were those of tubular degeneration and necrosis (8) .
During the course of a clinical study evaluating the therapeutic efficacy of bacitracin in human syphilis, 148 patients with early syphilis received the drug parenterally in dosages ranging from 200 units per kilogram body weight every 12 hours for four days up to 400 units per kilogram body weight every six hours for seven days. All of the 148 patients developed proteinuria during the course of therapy (9) . Characteristically, proteinuria was absent at 36 hours after the institution of parenteral bacitracin therapy and present at 60 hours. Urinary protein was at a maximum during the first 24 or 48 hours after its appearance and then decreased rapidly in spite of continuation of bacitracin therapy. The range of maximal proteinuria in individuals was from 0.1 gram to 19.6 grams in 24 hours, with a mean of 5.6 grams.
Microscopic examination of the urine revealed numerous epithelial cells and casts during the period of proteinuria. Red blood cells were present only rarely.
There was no relationship in this group of patients between the degree of proteinuria and either the daily dosage of the drug, the total amount of drug administered, or the duration of the therapeutic course. Furthermore, no difference in nephrotoxicity was discernible between various lots of bacitracin in spite of the fact that later preparations were considerably improved with regard to purity and potency.' There was, however, great individual variation in nephrotoxicity as measured by quantitative determination of urinary protein in patients receiving the same lot in the same dosage schedule.
In Figure 1 are shown the mean daily values for proteinuria in a group of 29 patients with early syphilis who received 400 units of bacitracin per kilogram body weight at six hour intervals over a period of seven days. Figure 2 shows, in similar fashion, proteinuria in a group of 15 patients with early syphilis who received only two injections of bacitracin of 1,500 units per kilogram body weight 24 hours apart. The curves are essentially the same. Similar curves of proteinuria were obtained in individuals receiving but a single injection of bacitracin and in individuals receiving the drug in dosages of 200 to 400 units per kilogram body weight at six to 12 hour intervals over a period of four to seven days. It is of interest that proteinuria appeared at the same time in all groups. Also of interest is the rapid decline in the magnitude of proteinuria (Figure 1) Following baseline determinations of the above functions as well as of blood non-protein nitrogen and urea nitrogen, bacitracin2 was administered intramuscularly in a dosage of 1,500 units per kilogram body weight followed by a second injection of the same magnitude 24 hours later. This dosage was selected to correspond to the daily therapeutic dosage employed by others in the treatment of various surgical and medical infections (2, 4, 5) . Two different lots of bacitracin, Lot B129 (Ben Venue) and Lot B480210 (Commercial Solvents), were used in the present study. The group in which TmPAH was followed received Lot B129, while the group in which Tm0 was followed received Lot B480210.
Subsequent to the administration of bacitracin, renal function studies and blood chemistry determinations were repeated at three to seven day intervals until baseline or near baseline values were again reached. Serial quantitative determinations of 24 hour urinary protein as well as routine urinalyses including microscopic examination of sediment of freshly voided urine were performed daily for 30 to 60 days following the administration of bacitracin.
Inulin was determined by Harrison's modification of the method of Alving (13, 14) . PAH was determined in cadmium sulfate filtrates of plasma and in diluted urine by the method of Bratton and Marshall (15) . Glucose determinations were made according to the method of Nelson (16) . Urinary protein was determined by measurement of the volume of precipitate formed with phosphotungstic acid in acid alcohol (17) . Blood urea nitrogen and non-protein nitrogen were determined by the manometric methods of Van Slyke (18, 19) .
RESULTS
Following the parenteral administration of bacitracin, proteinuria appeared at 48 to 60 hours in all subjects, was at a maximum for 48 hours after its appearance, and then decreased rapidly to levels below 0.5 gram per day by the seventh day in 11 of 12 subjects (Table I) Concomitantly with the onset of proteinuria, there appeared in the urine numerous tubular epithelial cells together with granular, hyaline, and epithelial cell casts. The absence of microscopic hematuria was striking. Epithelial cells and casts were present in large numbers in the urine for 48 hours, following which they paralleled proteinuria in their disappearance. Fasting glycosuria occurred during the period of proteinuria in 10 of 12 subjects.
Renal function studies were performed 84 hours after the administration of bacitracin, i.e., during the period of maximal proteinuria, in all subjects. The clearance of inulin (CIN) was depressed at this time in 10 of 12 subjects. The depression ranged from 6.7 to 74.6 per cent with a mean of 33.6 per cent. The mean depression for the entire group of 12 subjects was 27.6 per cent (Tables II  and III) . Following the period of proteinuria, the mean for the group gradually increased until, at nine weeks, it was only 8 per cent below the baseline value (Figures 3 and 4) . Of the 10 subjects who showed a decrease in CIN following bacitracin, nine had returned to within 15 per cent of baseline value by the ninth week. The tenth subject was lost to the study at seven weeks with a depression of 20.5 per cent. Furthermore, disparity between CIN and Tm depressions occurred in individual patients. In subjects E. N. and L. R., TmpAH returned to control levels over a period of one month following bacitracin, while CIN remained persistently depressed. This would seem to indicate impairment in glomerular function beyond four weeks which cannot be explained on the basis of passive diffusion of inulin through damaged tubules.
It would seem most likely, then, that the decrease in CIN observed cannot be entirely accounted for by mechanical obstruction of tubules and/or passive diffusion of inulin back through damaged tubular cells, and that injury to the glomerulus itself probably occurred.
The depression observed in CPAH might be explained on the basis of a decreased renal plasma flow or on the basis of reduced ability of damaged tubules to extract PAH at low plasma levels. It it evident from the results obtained in the additional subject studied by catheterization of the renal vein before and after bacitracin (Table IV) that the depression in CPAH was due largely to tubular damage rather than to a decrease in renal plasma flow. As contrasted with a decrease of 88. 4 sence of change in arterial blood pressure, and by the observation that the mean CPAH returned to baseline values at four weeks, while the mean CIN was still depressed at nine weeks following bacitracin. Additional evidence of tubular damage is presented by the appearance of tubular epithelial cells in the urine, the occurrence of glycosuria in the post-absorptive state, and the depression in tubular excretory and reabsorptive capacity for PAH and glucose respectively. Load to Tm ratios were as high in the post-bacitracin studies (i.e., 2: 1 to 3: 1) as in the control studies.
SUMMARY AND CONCLUSIONS 1. Parenteral administration of the polypeptide antibiotic substance, bacitracin, in therapeutic doses is followed uniformly by the occurrence of proteinuria and the appearance of renal tubular epithelial cells in the urine, and frequently by the occurrence of glycosuria in the post-absorptive state.
2. During the period of proteinuria there occurs an acute depression of tubular function and probably also of glomerular function, as manifested by a decrease in the clearances of inulin and PAH, a decrease in the tubular excretory capacity for PAH, a decrease in the tubular reabsorptive capacity for glucose, and a decrease in the renal extraction of PAH at low plasma levels.
3. Although proteinuria is present for only six to 10 days following two injections of 1,500 units of bacitracin per kilogram body weight, both glomerular and tubular function remain depressed over a period of weeks, returning only gradually to baseline levels at seven to nine weeks.
Since this work was submitted for publication, a number of reports (21) (22) (23) (24) (25) , relating to the toxicity of bacitracin have appeared.
